Comparative efficacy of irbesartan/ hydrochlorothiazide and valsartan/hydrochlorothiazide combination in lowering blood pressure

A retrospective observational study in oman

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: To compare blood pressure (BP) control in patients receiving irbesartan/hydrochlorothiazide (HCTZ) and valsartan/HCTZ at a tertiary care university hospital in Oman. Subjects and Methods: This was a retrospective observational study, where 232 patients' medical records were reviewed during a 3-month period, July to September 2010, at Sultan Qaboos University Hospital in Oman. BP readings of the previous 6 months were also retrieved from the electronic medical records. Analyses were conducted using univariate statistical techniques. Results: The mean age of the cohort was 58 ± 11 years (range: 21-88). Sixty-nine (30%) patients were on the irbesartan/HCTZ combination (150/12.5 mg) and 163 (70%) were on the valsartan/HCTZ combination. The patients on the valsartan/HCTZ combination were divided into two subgroups: 117 (72%) received 160/12.5 mg and 46 (28%) 80/12.5 mg. Diabetic patients (43/69, 62%, vs. 61/163, 37%, p <0.001) and those with diabetic nephropathy (8/69, 12%, vs. 7/163, 4%, p = 0.039) were prescribed more often irbesartan/HCTZ than valsartan/HCTZ. In comparison to the valsartan/HCTZ cohort, the irbesartan/HCTZ group was associated with significant reductions in both systolic BP (SBP; -9 vs. -2 mm Hg; p = 0.021) and diastolic BP (DBP; -5 vs. 0 mm Hg; p = 0.022). BP reductions were noted more in diabetics than nondiabetics with the irbesartan/HCTZ patients associated with significant reductions in both SBP (-12 vs. 5.1 mm Hg; p <0.001) and DBP (-6.4 vs. 1.9 mm Hg; p = 0.001). Conclusions: The irbesartan/HCTZ combination was associated with significant reductions in both SBP and DBP when compared with the valsartan/HCTZ combination. Specifically, the reductions were noted more in diabetics than nondiabetics.

Original languageEnglish
Pages (from-to)265-269
Number of pages5
JournalMedical Principles and Practice
Volume22
Issue number3
DOIs
Publication statusPublished - Mar 2013

Fingerprint

irbesartan
Valsartan
Oman
Hydrochlorothiazide
Observational Studies
Retrospective Studies
Blood Pressure

Keywords

  • Diabetes mellitus
  • Hypertension
  • Irbesartan
  • Nephropathy
  • Valsartan

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{62b01c43d9d1499fb515139b0d70fd01,
title = "Comparative efficacy of irbesartan/ hydrochlorothiazide and valsartan/hydrochlorothiazide combination in lowering blood pressure: A retrospective observational study in oman",
abstract = "Objective: To compare blood pressure (BP) control in patients receiving irbesartan/hydrochlorothiazide (HCTZ) and valsartan/HCTZ at a tertiary care university hospital in Oman. Subjects and Methods: This was a retrospective observational study, where 232 patients' medical records were reviewed during a 3-month period, July to September 2010, at Sultan Qaboos University Hospital in Oman. BP readings of the previous 6 months were also retrieved from the electronic medical records. Analyses were conducted using univariate statistical techniques. Results: The mean age of the cohort was 58 ± 11 years (range: 21-88). Sixty-nine (30{\%}) patients were on the irbesartan/HCTZ combination (150/12.5 mg) and 163 (70{\%}) were on the valsartan/HCTZ combination. The patients on the valsartan/HCTZ combination were divided into two subgroups: 117 (72{\%}) received 160/12.5 mg and 46 (28{\%}) 80/12.5 mg. Diabetic patients (43/69, 62{\%}, vs. 61/163, 37{\%}, p <0.001) and those with diabetic nephropathy (8/69, 12{\%}, vs. 7/163, 4{\%}, p = 0.039) were prescribed more often irbesartan/HCTZ than valsartan/HCTZ. In comparison to the valsartan/HCTZ cohort, the irbesartan/HCTZ group was associated with significant reductions in both systolic BP (SBP; -9 vs. -2 mm Hg; p = 0.021) and diastolic BP (DBP; -5 vs. 0 mm Hg; p = 0.022). BP reductions were noted more in diabetics than nondiabetics with the irbesartan/HCTZ patients associated with significant reductions in both SBP (-12 vs. 5.1 mm Hg; p <0.001) and DBP (-6.4 vs. 1.9 mm Hg; p = 0.001). Conclusions: The irbesartan/HCTZ combination was associated with significant reductions in both SBP and DBP when compared with the valsartan/HCTZ combination. Specifically, the reductions were noted more in diabetics than nondiabetics.",
keywords = "Diabetes mellitus, Hypertension, Irbesartan, Nephropathy, Valsartan",
author = "{Al Balushi}, {K. A.} and Habib, {J. Q.} and I. Al-Zakwani",
year = "2013",
month = "3",
doi = "10.1159/000345389",
language = "English",
volume = "22",
pages = "265--269",
journal = "Medical Principles and Practice",
issn = "1011-7571",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Comparative efficacy of irbesartan/ hydrochlorothiazide and valsartan/hydrochlorothiazide combination in lowering blood pressure

T2 - A retrospective observational study in oman

AU - Al Balushi, K. A.

AU - Habib, J. Q.

AU - Al-Zakwani, I.

PY - 2013/3

Y1 - 2013/3

N2 - Objective: To compare blood pressure (BP) control in patients receiving irbesartan/hydrochlorothiazide (HCTZ) and valsartan/HCTZ at a tertiary care university hospital in Oman. Subjects and Methods: This was a retrospective observational study, where 232 patients' medical records were reviewed during a 3-month period, July to September 2010, at Sultan Qaboos University Hospital in Oman. BP readings of the previous 6 months were also retrieved from the electronic medical records. Analyses were conducted using univariate statistical techniques. Results: The mean age of the cohort was 58 ± 11 years (range: 21-88). Sixty-nine (30%) patients were on the irbesartan/HCTZ combination (150/12.5 mg) and 163 (70%) were on the valsartan/HCTZ combination. The patients on the valsartan/HCTZ combination were divided into two subgroups: 117 (72%) received 160/12.5 mg and 46 (28%) 80/12.5 mg. Diabetic patients (43/69, 62%, vs. 61/163, 37%, p <0.001) and those with diabetic nephropathy (8/69, 12%, vs. 7/163, 4%, p = 0.039) were prescribed more often irbesartan/HCTZ than valsartan/HCTZ. In comparison to the valsartan/HCTZ cohort, the irbesartan/HCTZ group was associated with significant reductions in both systolic BP (SBP; -9 vs. -2 mm Hg; p = 0.021) and diastolic BP (DBP; -5 vs. 0 mm Hg; p = 0.022). BP reductions were noted more in diabetics than nondiabetics with the irbesartan/HCTZ patients associated with significant reductions in both SBP (-12 vs. 5.1 mm Hg; p <0.001) and DBP (-6.4 vs. 1.9 mm Hg; p = 0.001). Conclusions: The irbesartan/HCTZ combination was associated with significant reductions in both SBP and DBP when compared with the valsartan/HCTZ combination. Specifically, the reductions were noted more in diabetics than nondiabetics.

AB - Objective: To compare blood pressure (BP) control in patients receiving irbesartan/hydrochlorothiazide (HCTZ) and valsartan/HCTZ at a tertiary care university hospital in Oman. Subjects and Methods: This was a retrospective observational study, where 232 patients' medical records were reviewed during a 3-month period, July to September 2010, at Sultan Qaboos University Hospital in Oman. BP readings of the previous 6 months were also retrieved from the electronic medical records. Analyses were conducted using univariate statistical techniques. Results: The mean age of the cohort was 58 ± 11 years (range: 21-88). Sixty-nine (30%) patients were on the irbesartan/HCTZ combination (150/12.5 mg) and 163 (70%) were on the valsartan/HCTZ combination. The patients on the valsartan/HCTZ combination were divided into two subgroups: 117 (72%) received 160/12.5 mg and 46 (28%) 80/12.5 mg. Diabetic patients (43/69, 62%, vs. 61/163, 37%, p <0.001) and those with diabetic nephropathy (8/69, 12%, vs. 7/163, 4%, p = 0.039) were prescribed more often irbesartan/HCTZ than valsartan/HCTZ. In comparison to the valsartan/HCTZ cohort, the irbesartan/HCTZ group was associated with significant reductions in both systolic BP (SBP; -9 vs. -2 mm Hg; p = 0.021) and diastolic BP (DBP; -5 vs. 0 mm Hg; p = 0.022). BP reductions were noted more in diabetics than nondiabetics with the irbesartan/HCTZ patients associated with significant reductions in both SBP (-12 vs. 5.1 mm Hg; p <0.001) and DBP (-6.4 vs. 1.9 mm Hg; p = 0.001). Conclusions: The irbesartan/HCTZ combination was associated with significant reductions in both SBP and DBP when compared with the valsartan/HCTZ combination. Specifically, the reductions were noted more in diabetics than nondiabetics.

KW - Diabetes mellitus

KW - Hypertension

KW - Irbesartan

KW - Nephropathy

KW - Valsartan

UR - http://www.scopus.com/inward/record.url?scp=84876016182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876016182&partnerID=8YFLogxK

U2 - 10.1159/000345389

DO - 10.1159/000345389

M3 - Article

VL - 22

SP - 265

EP - 269

JO - Medical Principles and Practice

JF - Medical Principles and Practice

SN - 1011-7571

IS - 3

ER -